US 12357650
Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation
granted A61KA61K2121/00A61K31/513
Quick answer
US patent 12357650 (Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation) held by Shuttle Pharmaceuticals, Inc. expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Shuttle Pharmaceuticals, Inc.
- Grant date
- Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2121/00, A61K31/513, A61K31/7072, A61K33/243